We are live on ! Find out more
BXRX

Baudax Bio, Inc. Common Stock
BXRX

Delisted

BXRX was delisted on the 15th of November, 2023.

Back to rankings

19 hedge funds and large institutions have $1.08M invested in Baudax Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 19 → 19 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

51% less capital invested

Capital invested by funds: $2.2M → $1.08M (-$1.12M)

Holders
19
Holders Change
–
Holders Change %
0%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$228K
2
Renaissance Technologies
Renaissance Technologies
New York
+$96.9K
3
SM
Sabby Management
Florida
+$33K
4
HF
HRT Financial
New York
+$27.3K
5
VF
Virtu Financial
New York
+$24K

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$416K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$78.3K
3
TSS
Two Sigma Securities
New York
-$23K
4
Jane Street
Jane Street
New York
-$19K
5
BlackRock
BlackRock
New York
-$8.65K

BXRX Hedge Fund Activity: Q2 2022 in Review

19 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2022, worth a combined $1.08M — down 51% from $2.2M a quarter earlier.

Fund positioning in BXRX was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Walleye Capital, opening a new position worth an estimated $228K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $416K sold.

  • 19 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $1.08M of Baudax Bio, Inc. Common Stock stock for Q2 2022, down 51% quarter-over-quarter.
  • 5 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2022 and 5 closed out, a net change of 0 holders.
  • The largest Baudax Bio, Inc. Common Stock buyer in Q2 2022 was Walleye Capital, an estimated $228K added.
  • The largest Baudax Bio, Inc. Common Stock seller in Q2 2022 was D.E. Shaw & Co, an estimated $416K sold.

Based on aggregated 13F filings for Q2 2022.